D. Castellano Gauna

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 175 citations · Full text

Platinum-based Therapy, Urology, Metastatic Urothelial Carcinoma +8

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Laurence Albigès, Nizar M. Tannir, Mauricio Burotto et al. · Annals of Oncology · 2020 · 25 citations

Checkmate 214, Urology, Oncology +8

697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

Thomas Powles, Michiel S. van der Heijden, D. Castellano Gauna et al. · Annals of Oncology · 2020 · 20 citations

Care Chemotherapy, Urology, Urologic Cancer Epidemiology +9

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

Joaquim Bellmunt Molins, Jesús García-Donás Jiménez, Begoña P. Valderrama et al. · Clinical Genitourinary Cancer · 2020 · 14 citations

Maja Study, Urology, Genitourinary Cancer +9